Escherichia coli Lipopolysaccharide (LPS) Antibody
299€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Escherichia coli Lipopolysaccharide (LPS) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx101772
tested applications
WB, IHC
Description
Mouse monoclonal antibody against LPS from the O55:B5 strain of E. coli.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Escherichia coli Lipopolysaccharide (LPS) |
| Host | Mouse |
| Reactivity | General |
| Recommended Dilution | IHC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG2b Kappa |
| Clone ID | Z563 |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | LPS |
| Background | Antibody anti-LPS |
| Status | RUO |
| Note | Concentration: 1 mg/ml - |
Descripción
Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-negative bacteria, playing a crucial role in the structural integrity of bacterial cells and acting as a potent activator of the immune system. Composed of lipid A, a core oligosaccharide, and an O-antigen polysaccharide, LPS is a critical factor in bacterial pathogenicity. Lipid A is the bioactive component that triggers immune responses by binding to the Toll-like receptor 4 (TLR4) complex on immune cells, leading to the activation of nuclear factor-kappa B (NF-κB) and the release of pro-inflammatory cytokines such as IL-6 and TNF-alpha. While LPS is essential for host defense, its excessive activation can result in septic shock, characterized by systemic inflammation, organ failure, and high mortality. Therapeutic strategies targeting LPS-TLR4 signaling pathways are being explored to manage sepsis and other inflammatory conditions.
Related Products
Human LPS IgG (lipopolysaccharide IgG) ELISA Kit
Ver Producto
Human LPS IgM (lipopolysaccharide IgM) ELISA Kit
Ver Producto